Updated: Feb 15, 2022
EMPIRI's co-founder Dr. Kyuson Yun will be presenting at the AACR, mini-symposium session "Ex Vivo Models for Understanding Genetic Variation, Metastasis, and Treatment Sensitivity" on our platform technology, "E-slice: A novel 3D culture platform for precision medicine". #medicine #technology #culture #precisionmedicine #precisiononcology #cancerdiagnostics #aacr #drugdevelopment #drugdiscovery #pharmaceutical
We are excited to share that Kyuson Yun, co-founder of Empiri, will be presenting at the 10x Genomics User Group Meeting. This is a...
EMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front...
Funding to support a cancer diagnostic system to measure empirical treatment response Houston, TX, July 20, 2023 - EMPIRI, Inc., who is...
Comments